Pfizer Bolsters RSV Pipeline with US$525 M ReViral Acquisition
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 4 (Table of Contents)
Published: 15 Apr-2022
DOI: 10.3833/pdr.v2022.i4.2684 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In an attempt to expand its infectious disease portfolio, Pfizer has agreed to acquire respiratory syncytial virus (RSV) drug developer, ReViral, for a total consideration of up to US$525 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS